Taking people in United StatesNo phase

Smartwatch and Exercise to Protect Muscle During Weight-Loss Medication

Tests a smartwatch with exercise reminders in adults starting incretin weight-loss medicines.

Key facts

Who runs it: Massachusetts General Hospital
Where: Boston, United StatesSee the site
Trial code: NCT07226947
Registry title: Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
Status: Recruiting
People taking part: 100 people, planned
Started: 24 Nov 2025
Expected to end: Jun 2027
Type of study: Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested: Smartwatch activity and body composition monitor
General guidance on recommended exercise
Record updated: 30 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who started incretin (GLP-1) therapy in the past 2 months or plan to start it. It tests a smartwatch with exercise reminders.

Age: 18 years or older (up to 99 years).
Sex: All sexes can join.
Disease stage: BMI of 25 kg/m2 or higher at screening.
Earlier treatment: Started liraglutide, semaglutide, tirzepatide or retatrutide within the past 2 months, or plan to start one. People switching because the earlier treatment did not work well enough can join.

Main reasons for not taking part

Pregnant now (positive urine hCG) or planning pregnancy in the next 6 months
BMI below 25 kg/m2 at screening
Unable to take part in a regular exercise program
Implanted pacemaker
Any factor that the principal investigator thinks would interfere with safely finishing the study

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

Age ≥ 18 years old at time of signing informed consent
Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment; Potential participants switching GLP1-RA therapies due to inadequate response to a prior treatment will be eligible for enrollment
Able to provide informed consent

Who cannot take part

Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months
BMI <25 kg/m2 at the time of screening
Unable to participate in a regular physical exercise program
Implanted pacemaker
Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 99 years old?

Where in United States

Diabetes Research CenterBoston, United StatesContact: Ben O Brenner, BSTaking people

About the trial

What the trial wants to find out

The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.

The 2 groups in the trial

Smartwatch activity monitorTreatment being tested
Participants will be provided a smartwatch to monitor activity and body composition monitor. They will also have exercise goals set with reminders on the watch.
Treatment: Smartwatch activity and body composition monitor and General guidance on recommended exercise
Usual guidanceExisting treatment, for comparison
Participants will receive general guidance on recommended exercise
Treatment: General guidance on recommended exercise